4.6 Article

Olfactory Dysfunction Is Associated with Neuropsychiatric Manifestations in Parkinson's Disease

期刊

MOVEMENT DISORDERS
卷 26, 期 11, 页码 2051-2057

出版社

WILEY
DOI: 10.1002/mds.23792

关键词

Parkinson's disease; olfaction; nonmotor symptoms; psychiatric symptoms; cognitive symptoms

资金

  1. NIH [K23 MH067894, NINDS U10 NS044451-023, NINDS P50 NS053488-01, NINDS R43NS0636071, NINDS R01NS065087]
  2. Teva Pharmaceutical Industries Ltd.
  3. Avid Radiopharmaceuticals, Inc.
  4. Boehringer Ingelheim
  5. National Institutes of Health [NIMH K23 MH067894]
  6. NINDS [P50 NS053488-01, R01NS065087]
  7. NIA [RO1AG031348]
  8. Michael J. Fox Foundation for Parkinson's Research
  9. Institute for Neurodegenerative Disorders
  10. U.S. Department of Veterans Affairs
  11. Michael J. Fox Foundation
  12. Samueli Institute
  13. C.R. Bard, Inc.
  14. Celgene
  15. Clarient, Inc.
  16. Johnson Johnson

向作者/读者索取更多资源

Hyposmia, psychiatric disorders, and cognitive problems are common nonmotor manifestations in Parkinson's disease, but how they are related remains unclear. We investigated the relationship between olfactory dysfunction and neuropsychiatric manifestations and performed a cross-sectional study of 248 patients at two movement disorders clinics at academic medical centers. Psychiatric measures were the Geriatric Depression Scale-15, Inventory of Depressive Symptomatology, State Anxiety Inventory, Apathy Scale, and Parkinson's Psychosis Rating Scale. Cognitive measures were the Mini-Mental State Examination, Hopkins Verbal Learning Test-Revised, Digit Span, Tower of London-Drexel, and the Stroop Color Word Test. Olfaction was tested with the University of Pennsylvania Smell Identification Test. There was no significant association between olfaction and mood measures, but psychotic symptoms were more common in patients with olfaction scores below the median (30% vs. 12%; P < 0.001). Worse olfaction was associated with poorer memory (Hopkins Verbal Learning Test-Revised delayed recall items: mean [standard deviation], 6.2 [3.2] vs. 8.4 [2.8]; P < 0.001) and executive performance (Tower of London total moves, 52 [38] vs. 34 [21]; P < 0.001). Odor-identification score was a significant predictor of abnormal performance on these cognitive tests after adjustment for age, sex, and disease characteristics in logistic regression models. The relationship between hyposmia, psychosis, and specific cognitive impairments may reflect the anatomic distribution of Lewy pathology and suggests that olfactory dysfunction could be a biomarker of additional extranigral disease. Future prospective studies are warranted to assess whether hyposmia, a very early feature of Parkinson's disease, might be used to predict the appearance of other common nonmotor symptoms. (C) 2011 Movement Disorder Society

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease

Thomas Guttuso, Daniel Sirica, Duygu Tosun, Robert Zivadinov, Ofer Pasternak, Daniel Weintraub, Francesca Baglio, Niels Bergsland

Summary: This study assessed the free water content changes in cognitive-relevant brain regions in early Parkinson's disease patients and their correlation with cognitive decline over time and baseline cognitive status. Results showed that free water was the most robust assessment modality for these outcomes and may assist in identifying cognition protective therapies in clinical trials.

MOVEMENT DISORDERS (2022)

Article Neurosciences

A Patient-Centered Conceptual Model of Symptoms and Their Impact in Early Parkinson's Disease: A Qualitative Study

Hannah Staunton, Kim Kelly, Louise Newton, Mathias Leddin, Raul Rodriguez-Esteban, K. Ray Chaudhuri, Daniel Weintraub, Ronald B. Postuma, Pablo Martinez-Martin

Summary: This study aims to create a conceptual model of symptoms and impacts for individuals with early-stage Parkinson's disease (PD) by collecting qualitative data. The results show that the most frequently reported symptoms in early-stage PD include tremors, stiffness and rigidity, and fatigue, while the most commonly reported impacts include anxiety, eating and drinking, and exercise/sport and relationship with family/family life. The conceptual model can be used to guide researchers in developing and selecting patient-centered outcomes for clinical trials and inform future qualitative research and outcome development specifically for early-stage PD patients.

JOURNAL OF PARKINSONS DISEASE (2022)

Article Clinical Neurology

Validation of the Japanese Version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)

Maiko Takahashi, Jinsoo Koh, Shoko Yorozu, Yoshinori Kajimoto, Yoshiaki Nakayama, Mayumi Sakata, Masaaki Yasui, Yasuhiro Hiwatani, Daniel Weintraub, Hidefumi Ito

Summary: The present study validated the Japanese version of QUIP-RS and determined the characteristics of ICBs in Japan. The use of QUIP-RS-J enables standardized assessment of ICBs and can be used in clinical research.

PARKINSONS DISEASE (2022)

Article Neurosciences

Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting

Lara Bloemeke, Marlene Pils, Victoria Kraemer-Schulien, Alexandra Dybala, Anja Schaffrath, Andreas Kulawik, Fabian Rehn, Anneliese Cousin, Volker Nischwitz, Johannes Willbold, Rebecca Zack, Thomas F. Tropea, Tuyen Bujnicki, Gultekin Tamgueney, Daniel Weintraub, David Irwin, Murray Grossman, David A. Wolk, John Q. Trojanowski, Oliver Bannach, Alice Chen-Plotkin, Dieter Willbold

Summary: The formation of toxic oligomers by proteins such as aSyn and Tau is a characteristic feature of neurodegenerative diseases. This study measured the concentrations of aSyn and Tau aggregates in cerebrospinal fluid samples from different diagnostic groups and found that sFIDA-based measurements can differentiate between these groups. The findings suggest that sFIDA has the potential to improve pre-clinical and clinical studies and identify individuals who are likely to respond to compounds designed to target specific oligomers.

NPJ PARKINSONS DISEASE (2022)

Article Clinical Neurology

Plasma phosphorylated tau181 predicts cognitive and functional decline

Thomas F. Tropea, Teresa Waligorska, Sharon X. Xie, Ilya M. Nasrallah, Katheryn A. Q. Cousins, John Q. Trojanowski, Murray Grossman, David J. Irwin, Daniel Weintraub, Edward B. Lee, David A. Wolk, Alice S. Chen-Plotkin, Leslie M. Shaw

Summary: The objective of this study was to determine if plasma tau phosphorylated at threonine 181 (p-tau181) can distinguish Alzheimer's disease (AD) from normal cognition (NC) in adults, predict cognitive and functional decline, and validate findings in an external cohort. The results showed that plasma p-tau181 can accurately differentiate AD pathology from NC, and higher levels of p-tau181 are associated with faster cognitive and functional decline.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Article Clinical Neurology

Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated

John L. Robinson, Sharon X. Xie, Daniel R. Baer, EunRan Suh, Vivianna M. Van Deerlin, Nicholas J. Loh, David J. Irwin, Corey T. McMillan, David A. Wolk, Alice Chen-Plotkin, Daniel Weintraub, Theresa Schuck, Virginia M. Y. Lee, John Q. Trojanowski, Edward B. Lee

Summary: In this retrospective study, the incidence of 10 pathologies in neurodegenerative disease (ND) and normal aging was examined, with up to seven pathologies observed concurrently resulting in 161 different combinations. The presence of multiple additive pathologies was associated with factors such as longer disease duration, clinical dementia, older age, and APOE e4 status.
Article Clinical Neurology

Channeling of New Neuropsychiatric Drugs-Impact on Safety and Effectiveness Studies

Danielle S. Abraham, Thanh Phuong Pham Nguyen, Leah J. Blank, Dylan Thibault, Shelly L. Gray, Sean Hennessy, Charles E. Leonard, Daniel Weintraub, Allison W. Willis

Summary: This study examined the differential prescribing patterns between new and established treatments for common neurological conditions. Using data from a national sample of US commercially insured adults from 2005-2019, the study compared new users of recently approved medications for three conditions: diabetic peripheral neuropathy, Parkinson disease psychosis, and epilepsy. The results showed that newer medications were more frequently prescribed to individuals with prior treatment, suggesting potential bias in comparative effectiveness and safety studies. The study emphasizes the importance of reporting propensity score non-overlap in comparative studies involving newer medications and suggests methodological approaches to address channeling bias.

NEUROTHERAPEUTICS (2023)

Article Clinical Neurology

Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease

Katheryn A. Q. Cousins, David J. Irwin, Alice Chen-Plotkin, Leslie M. Shaw, Sanaz Arezoumandan, Edward B. Lee, David A. Wolk, Daniel Weintraub, Meredith Spindler, Andres Deik, Murray Grossman, Thomas F. Tropea

Summary: This study found that plasma GFAP may be sensitive to concomitant AD pathology in LBSD, especially accumulation of beta-amyloid plaques.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Article Neurosciences

LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts

Kalpana M. Merchant, Tanya Simuni, Janel Fedler, Chelsea Caspell-Garcia, Michael Brumm, Kelly N. H. Nudelman, Elizabeth Tengstrandt, Frank Hsieh, Roy N. Alcalay, Christopher Coffey, Lana Chahine, Tatiana Foroud, Andrew Singleton, Daniel Weintraub, Samantha Hutten, Todd Sherer, Brit Mollenhauer, Andrew Siderowf, Caroline Tanner, Ken Marek

Summary: We quantified concentrations of three isoforms of BMP in different cohorts of Parkinson's disease patients and found that LRRK2 and GBA1 gene mutations were associated with elevated BMP levels. However, BMP is not a prognostic or disease progression biomarker.

NPJ PARKINSONS DISEASE (2023)

Article Clinical Neurology

Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study

Daniel Weintraub, Marina Picillo, Hyunkeun Ryan Cho, Chelsea Caspell-Garcia, Cornelis Blauwendraat, Ethan G. Brown, Lana M. Chahine, Christopher S. Coffey, Roseanne D. Dobkin, Tatiana Foroud, Doug Galasko, Karl Kieburtz, Kenneth Marek, Kalpana Merchant, Brit Mollenhauer, Kathleen L. Poston, Tanya Simuni, Andrew Siderowf, Andrew Singleton, John Seibyl, Caroline M. Tanner

Summary: This study used data from a multi-site, international, prospective cohort study to investigate the impact of dopamine system-related biomarkers on cognitive impairment in Parkinson's disease. The results showed that alterations in the dopamine system were associated with the development of cognitive impairment in Parkinson's disease. If confirmed causative, these findings suggest that the dopamine system is instrumental to cognitive health status throughout the disease course.

MOVEMENT DISORDERS CLINICAL PRACTICE (2023)

Article Clinical Neurology

Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial

Hubert H. Fernandez, Daniel Weintraub, Eric Macklin, Irene Litvan, Michael A. Schwarzschild, Jamie Eberling, Aleksandar Videnovic, Christopher J. Kenney

Summary: In patients with Parkinson disease dementia (PDD), SYN120 did not improve cognition significantly but showed potential benefits in cognitive activities of daily living and apathy.

PARKINSONISM & RELATED DISORDERS (2023)

Article Clinical Neurology

Potentially inappropriate medications in older adults with Parkinson disease before and after hospitalization for injury

Thanh Phuong Pham Nguyen, Shelly L. Gray, Craig W. Newcomb, Qing Liu, Ali G. Hamedani, Daniel Weintraub, Sean Hennessy, Allison W. Willis

Summary: This study found that there were no significant differences in medication prescriptions between Parkinson disease (PD) patients hospitalized for serious injury and those hospitalized for other reasons, indicating a missed opportunity to deprescribe high-risk medications during care transitions.

PARKINSONISM & RELATED DISORDERS (2023)

Article Clinical Neurology

The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP)

Vindhya Koneru, Alberto J. Espay, Allan J. Cole, Daniel Weintraub, Kathleen Crist, Maria B. Pascual, William G. Ondo

MOVEMENT DISORDERS (2023)

暂无数据